The key element in developing a successful malaria treatment is a good understanding of molecular mechanisms engaged in human host infection. It is assumed that oligosaccharides play a significant role in Plasmodium parasites binding to RBCs at different steps of host infection. The formation of a tight junction between EBL merozoite ligands and glycophorin receptors is the crucial interaction in ensuring merozoite entry into RBCs. It was proposed that sialic acid residues of O/N-linked glycans form clusters on a human glycophorins polypeptide chain, which facilitates the binding. Therefore, specific carbohydrate drugs have been suggested as possible malaria treatments. It was shown that the sugar moieties of N-acetylneuraminyl-N-acetate-lactosamine and 2,3-didehydro-2-deoxy-N-acetylneuraminic acid (DANA), which is its structural analog, can inhibit P. falciparum EBA-175-GPA interaction. Moreover, heparin-like molecules might be used as antimalarial drugs with some modifications to overcome their anticoagulant properties. Assuming that the principal interactions of Plasmodium merozoites and host cells are mediated by carbohydrates or glycan moieties, glycobiology-based approaches may lead to new malaria therapeutic targets.
The molecular mechanisms underlying host invasion by Plasmodium malaria parasites still require better understanding. The blood stage of the infection is particularly interesting because it is a key step in parasite invasion. Erythrocyte basigin (BSG) is a crucial receptor for the recognition of host red blood cells (RBCs), and blocking it can protect against this merozoite stage of infection.This work aims to determine the role of BSG N‑glycans in the binding of the P. falciparum Rh5 ligand. We obtained recombinant human BSG, its glycosylation mutants, and the recombinant P. falciparum Rh5 protein. Four glycosylation mutants of BSG, lacking one of the three N‑glycoside chains linked to asparagine 44, 152, or 186, and a deglycosylated variant, allowed for the examination of BSG binding by the Rh5 ligand. All recombinant proteins were obtained in mammalian HEK293F cells and characterized for purity by SDS‑PAGE and Western blotting. The SPR technique was used to analyze BSG binding to the Rh5 protein. Our results show that the removal of any BSG N‑glycan increased Rh5 ligand binding to the recombinant BSG. It might suggest that all BSG glycans, and especially the N44 glycan, not only participate in Rh5 binding but also hinder it. We propose that BSG glycosylation might be a human evolutionary adaptation that prevents erythrocyte invasion by Plasmodium parasites.